Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025
Qigu capsule alleviates dexamethasone-induced muscle dysfunction through mitochondrial biogenesis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jinyu Shi, Haiya G E, Zongrui Yang, Hongsheng Zhan
Аннотация
OBJECTIVE: To explore the potential molecular mechanism of Qigu capsule (，QGC) improve the functional performance of skeletal muscle.
METHODS: The primary components of QGC were analyzed using high-performance liquid chromatography (HPLC). Muscle dysfunction was established in male C57BL/6 mice treated with dexamethasone (1 mg/kg body weight, i.p., six weeks). Rotarod test, mitochondrial ultrastructure, respiratory chain complex V activity, succinate dehydrogenase (SDH) activity, adenosine triphosphate (ATP) content, and reactive oxygen species (ROS) levels were assessed. The mitochondrial biogenesis-related protein expressions were analyzed using Western blot or polymerase chain reaction (PCR).
RESULTS: QGC treatment enhanced Rotarod test performance. Additionally, QGC significantly alleviated dexamethasone-induced mitochondrial damage, reduced mitochondrial swelling, increased respiratory chain complex enzyme activity, SDH activity, ATP content, and decreased ROS levels. PCR and western blot results revealed that QGC enhanced mitochondrial biogenesis via adenosine 5'-monophosphate-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor-γ coactivator 1-alpha (PGC-1α) signaling pathway.
CONCLUSIONS: QGC ameliorates dexamethasone-induced skeletal muscle dysfunction by activating AMPK/ PGC-1α, which might be developed as a therapeutic agent for treating age-related muscle weakness.
METHODS: The primary components of QGC were analyzed using high-performance liquid chromatography (HPLC). Muscle dysfunction was established in male C57BL/6 mice treated with dexamethasone (1 mg/kg body weight, i.p., six weeks). Rotarod test, mitochondrial ultrastructure, respiratory chain complex V activity, succinate dehydrogenase (SDH) activity, adenosine triphosphate (ATP) content, and reactive oxygen species (ROS) levels were assessed. The mitochondrial biogenesis-related protein expressions were analyzed using Western blot or polymerase chain reaction (PCR).
RESULTS: QGC treatment enhanced Rotarod test performance. Additionally, QGC significantly alleviated dexamethasone-induced mitochondrial damage, reduced mitochondrial swelling, increased respiratory chain complex enzyme activity, SDH activity, ATP content, and decreased ROS levels. PCR and western blot results revealed that QGC enhanced mitochondrial biogenesis via adenosine 5'-monophosphate-activated protein kinase (AMPK)/peroxisome proliferator-activated receptor-γ coactivator 1-alpha (PGC-1α) signaling pathway.
CONCLUSIONS: QGC ameliorates dexamethasone-induced skeletal muscle dysfunction by activating AMPK/ PGC-1α, which might be developed as a therapeutic agent for treating age-related muscle weakness.
Предметные рубрики MeSH
AnimalsDexamethasoneMaleMiceMice, Inbred C57BLOrganelle BiogenesisDrugs, Chinese HerbalMitochondriaMuscle, SkeletalAMP-Activated Protein KinasesHumansReactive Oxygen SpeciesMuscular DiseasesPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaCapsulesAdenosine TriphosphateSignal Transduction